Next, to validate the prognostic role of GATM, we evaluated the GATM protein expression via IHC staining in 51 metastatic ccRCC patients and stratified it into two groups according to the status of GATM expression (GATM-positive and GATM-negative, respectively) (Figure 5A). This evidence concerns the gene GATM and nonpapillary renal cell carcinoma.